226 related articles for article (PubMed ID: 22987603)
1. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
Lankheet NA; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH; Huitema AD
Biomed Chromatogr; 2013 Apr; 27(4):466-76. PubMed ID: 22987603
[TBL] [Abstract][Full Text] [Related]
2. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Herbrink M; de Vries N; Rosing H; Huitema AD; Nuijen B; Schellens JH; Beijnen JH
Ther Drug Monit; 2016 Dec; 38(6):649-656. PubMed ID: 27749781
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
4. An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.
Couchman L; Birch M; Ireland R; Corrigan A; Wickramasinghe S; Josephs D; Spicer J; Flanagan RJ
Anal Bioanal Chem; 2012 Jun; 403(6):1685-95. PubMed ID: 22526649
[TBL] [Abstract][Full Text] [Related]
5. A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Lankheet AG; Hillebrand MJ; Langenberg MH; Rosing H; Huitema AD; Voest EE; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3625-30. PubMed ID: 19762293
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Andriamanana I; Gana I; Duretz B; Hulin A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():83-91. PubMed ID: 23562906
[TBL] [Abstract][Full Text] [Related]
7. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma.
Götze L; Hegele A; Metzelder SK; Renz H; Nockher WA
Clin Chim Acta; 2012 Jan; 413(1-2):143-9. PubMed ID: 21945732
[TBL] [Abstract][Full Text] [Related]
8. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
Roche S; McMahon G; Clynes M; O'Connor R
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(31):3982-90. PubMed ID: 19854117
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS.
Huynh HH; Pressiat C; Sauvageon H; Madelaine I; Maslanka P; Lebbé C; Thieblemont C; Goldwirt L; Mourah S
Ther Drug Monit; 2017 Feb; 39(1):43-54. PubMed ID: 27861317
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A
Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048
[TBL] [Abstract][Full Text] [Related]
11. A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
van Erp NP; de Wit D; Guchelaar HJ; Gelderblom H; Hessing TJ; Hartigh Jd
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Oct; 937():33-43. PubMed ID: 24013127
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.
Bouchet S; Chauzit E; Ducint D; Castaing N; Canal-Raffin M; Moore N; Titier K; Molimard M
Clin Chim Acta; 2011 May; 412(11-12):1060-7. PubMed ID: 21345336
[TBL] [Abstract][Full Text] [Related]
13. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry.
Honeywell R; Yarzadah K; Giovannetti E; Losekoot N; Smit EF; Walraven M; Lind JS; Tibaldi C; Verheul HM; Peters GJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 May; 878(15-16):1059-68. PubMed ID: 20382575
[TBL] [Abstract][Full Text] [Related]
14. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.
Chahbouni A; den Burger JC; Vos RM; Sinjewel A; Wilhelm AJ
Ther Drug Monit; 2009 Dec; 31(6):683-7. PubMed ID: 19865001
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
Zhao J; Yan D; Li Y; Xu X; Li F; Zhang S; Jin J; Qiu F
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Apr; 1237():124100. PubMed ID: 38547701
[TBL] [Abstract][Full Text] [Related]
17. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
ter Heine R; Alderden-Los CG; Rosing H; Hillebrand MJ; van Gorp EC; Huitema AD; Beijnen JH
Rapid Commun Mass Spectrom; 2007; 21(15):2505-14. PubMed ID: 17610214
[TBL] [Abstract][Full Text] [Related]
18. High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS.
Merienne C; Rousset M; Ducint D; Castaing N; Titier K; Molimard M; Bouchet S
J Pharm Biomed Anal; 2018 Feb; 150():112-120. PubMed ID: 29220734
[TBL] [Abstract][Full Text] [Related]
19. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Hirasawa T; Kikuchi M; Shigeta K; Takasaki S; Sato Y; Sato T; Ogura J; Onodera K; Fukuhara N; Onishi Y; Maekawa M; Mano N
Biomed Chromatogr; 2021 Aug; 35(8):e5124. PubMed ID: 33772839
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
